---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-033743"
form_type: "8-K"
ticker: "VNDA"
cik: "0001347178"
company_name: "Vanda Pharmaceuticals Inc."
filed_at: "2024-07-31T23:59:59+00:00"
generated_at: "2026-05-31T14:18:34.660002+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Vanda Q2 2024 revenue $50.5M (+10% YoY); net loss $4.5M; Fanapt bipolar launch underway

## Summary
- Q2 2024 total revenues $50.5M (up 10% YoY); net loss $4.5M vs net income $1.5M in Q2 2023.
- Fanapt approved for bipolar I disorder; commercial launch initiated in Q3 2024; PONVORY launch for MS also started.
- Tradipitant NDA for gastroparesis under FDA review; PDUFA date Sept 18, 2024; FDA preliminary notice of deficiencies.
- HETLIOZ net sales $18.7M (-15% YoY) amid generic competition; lawsuit vs Teva/Apotex allowed to proceed.
- Full-year 2024 guidance: total revenues $180-210M; year-end cash $360-390M; cash $387.7M at June 30.

## SEC filing metadata
- accession: 0001628280-24-033743
- form_type: 8-K
- ticker: VNDA
- cik: 0001347178
- company_name: Vanda Pharmaceuticals Inc.
- filed_at: 2024-07-31T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1347178/000162828024033743/0001628280-24-033743-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1347178/000162828024033743/vnda-20240731.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-033743
- JSON: https://secwatch.observer/filing/0001628280-24-033743.json
- Plain text: https://secwatch.observer/filing/0001628280-24-033743.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.